Advertisement

European Journal of Clinical Pharmacology

, Volume 63, Issue 2, pp 151–158 | Cite as

Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

  • Paul L. M. van Giersbergen
  • Jasper Dingemanse
Pharmacokinetics and Disposition

Abstract

Objective

The purpose of this study was to investigate in healthy male subjects the tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of clazosentan, an intravenous endothelin receptor antagonist.

Methods

Clazosentan was infused at doses of 3–60 mg/h for 3 h, 60 mg/h for 6 h and at 30 mg/h for 12 h. Each dose was given to a separate group of subjects, six of whom received clazosentan and two placebo. Vital signs, ECG, adverse events, and clinical laboratory variables were monitored to assess tolerability. Blood and urine samples were collected frequently for pharmacokinetic and pharmacodynamic determinations.

Results

Infusion of clazosentan up to doses of 30 mg/h for 3 h was well tolerated. A dose of 60 mg/h and longer infusions were less well tolerated and three subjects did not complete the 12-h infusion of 30 mg/h due to adverse events. Headache was the most commonly reported adverse event followed by nausea, vomiting, and nasal congestion. The pharmacokinetics of clazosentan were dose proportional in the dose range investigated. Values (mean and 95% confidence intervals) for clearance and volume of distribution at a dose of 10 mg/h for 3 h were 42.2 (36.6, 48.7) l/h and 32.4 (27.0, 38.8) l, respectively. Both variables were independent of dose. The elimination of clazosentan was characterized by a very rapid disposition phase with a half-life of 6–10 min. Compared to baseline, endothelin-1 concentrations increased approximately 2-fold after infusion of clazosentan but no dose-dependent relationship could be discerned for this effect.

Conclusion

The observed tolerability, pharmacokinetic, and pharmacodynamic profile warrant further clinical development of clazosentan at lower doses.

Keywords

Clazosentan ET receptor antagonist Intravenous administration Entry-into-man study 

Notes

Acknowledgements

This study was conducted at the Roche Clinical Pharmacology Unit, Strasbourg, France with Dr. Rainer Schulz as medical investigator. The study was sponsored by F. Hoffmann-La Roche, Basel, Switzerland. The experiments described in this paper comply with the current laws of France inclusive of ethics approval.

References

  1. 1.
    Pernow J, Ahlborg G, Lundberg JM, Kaijser L (1997) Long-lasting coronary vasoconstrictor effects and myocardial uptake of endothelin-1 in humans. Acta Physiol Scand 159:147–153PubMedCrossRefGoogle Scholar
  2. 2.
    Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415PubMedCrossRefGoogle Scholar
  3. 3.
    Lüscher TF, Barton M (2000) Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434–2440PubMedGoogle Scholar
  4. 4.
    Spieker LE, Noll G, Luscher TF (2001) Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs 1:293–303PubMedCrossRefGoogle Scholar
  5. 5.
    Ray A, Hegde LG, Chugh A, Gupta JB (2000) Endothelin-receptor antagonists: current and future perspectives. Drug Discov Today 5:455–464PubMedCrossRefGoogle Scholar
  6. 6.
    Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M (1997) Ro 61–1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283:1110–1118PubMedGoogle Scholar
  7. 7.
    Dorsch NWC, King MT (1994) A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage. J Clin Sci 1:19–26Google Scholar
  8. 8.
    Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled multicenter Phase IIa study. J Neurosurg 103:9–17PubMedCrossRefGoogle Scholar
  9. 9.
    Treinen KA, Louden C, Dennis MJ, Wier PJ (1999) Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 59:51–59PubMedCrossRefGoogle Scholar
  10. 10.
    Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New YorkGoogle Scholar
  11. 11.
    Gough K, Hutchison M, Keene O Byrom B, Ellis S, Lacey L, McKellar J (1995) Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 29:1039–1048Google Scholar
  12. 12.
    Buoen C, Bjerrum OJ, Thomsen MS (2005) How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol 45:1123–1136PubMedCrossRefGoogle Scholar
  13. 13.
    Dingemanse J, Clozel M, van Giersbergen PLM (2002) Entry-into-man study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol 39:795–802PubMedCrossRefGoogle Scholar
  14. 14.
    Weber C, Schmitt R, Birnboeck H, Hopfgartner G, van Marle SP, Peeters PAM, Jonkman JHG (1996) Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–137PubMedCrossRefGoogle Scholar
  15. 15.
    Freed MI, Wilson DE, Thompson KA, Harris RZ, Ilson BE, Jorkasky DK (1999) Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone. Clin Pharmacol Ther 65:473–482PubMedCrossRefGoogle Scholar
  16. 16.
    Dingemanse J, Clozel M, van Giersbergen PLM (2002) Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol 53:355–362PubMedCrossRefGoogle Scholar
  17. 17.
    van Giersbergen PLM, Bodin F, Dingemanse J (2002) Cyclosporine increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist. Eur J Clin Pharmacol 58:243–245PubMedCrossRefGoogle Scholar
  18. 18.
    Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97:752–756PubMedGoogle Scholar
  19. 19.
    Dingemanse J, Gunawardena KA, van Giersbergen PLM (2006) Comparison of the pharmacokinetics, pharmacodynamics, and tolerability of tezosentan between Caucasian and Japanese subjects. Br J Clin Pharmacol 61:405–413PubMedCrossRefGoogle Scholar
  20. 20.
    Hamadeh MJ, Robitaille L, Boismenu D, Hongsprabhas P, Mamer OA, Hoffer LJ (1999) Human extracellular water volume can be measured using the stable isotope Na2 34SO4. J Nutr 129:722–727PubMedGoogle Scholar
  21. 21.
    Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M (1994) Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 199:1461–1465PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Paul L. M. van Giersbergen
    • 1
  • Jasper Dingemanse
    • 1
  1. 1.Department of Clinical PharmacologyActelion Pharmaceuticals LtdAllschwilSwitzerland

Personalised recommendations